(2) Cardiovascular disease and glycemic control in type 2 diabetes: now that the dust is settling from large clinical trials [PubMed Abstract] [Full Text HTML] [Full Text PDF]
Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.
ChoosingTherapy.com is compensated for marketing by the companies included below
While the evidence regarding GLP-1 receptor expression in testosterone-producing tissues is limited and mixed in humans, the metabolic changes induced by semaglutideparticularly significant weight loss and improved insulin sensitivitycan indirectly affect hormone balance
There is less subcutaneous depot formation, less post-injection tenderness, and less visible injection site reaction
However, in some cases, underlying factorssuch as receptor resistance, lifestyle misalignment, nutrient gaps, or dosing issuesmay need to be addressed to achieve results again
